|24th February 2021||Michael J Brown||2,249||Payment by withholding||$156.27||$351,451.23|
|24th February 2021||Michael J Brown||7,236||Grant/award etc.||$0.00|
|1st January 2021||Chandler Robinson||2,327||Payment by withholding||$6.12||$14,241.24|
|1st January 2021||Chandler Robinson||6,724||Exercise of derivative||$0.00|
|1st January 2021||Kim R Tsuchimoto||1,231||Exercise of derivative||$0.00|
|1st January 2021||Andrew Paul Mazar||1,937||Exercise of derivative||$0.00|
|1st January 2021||Kim R Tsuchimoto||504||Payment by withholding||$6.12||$3,084.48|
|1st January 2021||Andrew Paul Mazar||671||Payment by withholding||$6.12||$4,106.52|
|31st December 2020||Michael J Brown||322||Exercise of derivative||$0.00|
|31st December 2020||Arthur J Klausner||322||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014.